⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MNOV News
Medicinova, Inc.
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
globenewswire.com
MNOV
MediciNova to Participate at the 38th Annual ROTH Conference
globenewswire.com
MNOV
Form 8-K
sec.gov
MNOV
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
globenewswire.com
MNOV
2026 New Year’s Greetings from the CEO
globenewswire.com
MNOV
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
globenewswire.com
MNOV
Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight
prnewswire.com
NRSN
IONQ
MNOV
CLNN
RVSN
BIIB
ABSI
CLNE
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
globenewswire.com
MNOV
Message from the CEO to MediciNova Shareholders
globenewswire.com
MNOV
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
globenewswire.com
MNOV